In patients with type 2 diabetes and established atherosclerotic CVD or multiple CV risk factors, an SGLT2 inhibitor or GLP-1 receptor agonist with demonstrated CV benefit is recommended to reduce the risk of MACE, whereas SGLT2 inhibitors are further recommended in these patients to reduce the risk of hospitalization for HF and in those with diabetic kidney disease [127]. Here, SLC5A2 is linked to type 2 diabetes mellitus.